SAGE Therapeutics (SAGE), Biogen (BIIB) to Submit NDA for Zuranolone to FDA in Second Half of 2022 with Rolling Submission Expected to Start in Early 2022

Go back to SAGE Therapeutics (SAGE), Biogen (BIIB) to Submit NDA for Zuranolone to FDA in Second Half of 2022 with Rolling Submission Expected to Start in Early 2022

Long-term Prospects for Biogen’s (BIIB) Aduhelm Remain Key Question - Analyst

October 20, 2021 8:21 AM EDT

Earlier today, Biogen (NASDAQ: BIIB) reported Q3 results: EPS of $4.77, $0.66 better than the analyst estimate of $4.11; revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.

The company also updated its full-year guidance: EPS of $18.85-$19.35, versus the consensus of $18.61; FY2021... More